A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype

Oncogene

Volumn 35, Issue 46, 2016, Pages 6026-6037

  Fessler, E ^a,b   Jansen, M ^a,g   De Sousa E Melo, F ^a,b,h   Zhao, L ^c   Prasetyanti, P R ^a,b   Rodermond, H ^a,b   Kandimalla, R ^a,b   Linnekamp, J F ^a,b   Franitza, M ^d,e   Van Hooff, S R ^a,b   De Jong, J H ^a,b   Oppeneer, S C ^a   Van Noesel, C J M ^a   Dekker, E ^a   Stassi, G ^f   Wang, X ^c,h   Medema, J P ^a,b   Vermeulen, L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Cancer Genomics Center   (Netherlands)

^c CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF PALERMO   (Italy)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 200; MIRN200 MICRORNA, HUMAN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; MALE; MESENCHYME; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; BIOLOGY; COLORECTAL TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; MORTALITY; MULTIGENE FAMILY; PATHOLOGY; PHENOTYPE; PROCEDURES; PROGNOSIS; TUMOR CELL LINE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MALE; MICRORNAS; MULTIGENE FAMILY; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TRANSCRIPTOME;

EID: 84966668047     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.134     Document Type: Article

References (49)

1. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012; 5.
2. De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-618.
3. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625.
4. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231: 63-76.
5. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014; 134: 552-562.
6. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013; 10.
7. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356.
8. Wang X, Markowetz F, De Sousa E, Melo F, Medema JP, Vermeulen L. Dissecting cancer heterogeneity-an unsupervised classification approach. Int J Biochem Cell Biol 2013; 45: 2574-2579.
9. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318-325.
10. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013; 23: 186-199.
11. Song F, Yang D, Liu B, Guo Y, Zheng H, Li L et al. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res 2014; 20: 878-889.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
13. Selbach M, Schwanhaüsser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455: 58-63.
14. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
15. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9: 293-302.
16. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
17. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
18. Park S-M, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
19. Tian Y, Pan Q, Shang Y, Zhu R, Ye J, Liu Y et al. MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells. J Biol Chem 2014; 289: 36101-36115.
20. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013; 15: 180-191.
21. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013; 62: 1315-1326.
22. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter H-I et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res notes 2010; 3.
23. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PloS One 2010; 5.
24. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327-1334.
25. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012; 31: 2062-2074.
26. Sugai T, Habano W, Jiao Y-F, Tsukahara M, Takeda Y, Otsuka K et al. Analysis of molecular alterations in left-and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis. J Mol Diagn 2006; 8: 193-201.
27. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
28. The Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
29. Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 2011; 13.
30. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589.
31. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci 2010; 107: 15449-15454.
32. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670-677.
33. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015; 47: 312-319.
34. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015; 47: 320-329.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
36. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
37. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
38. Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006; 94: 1816-1822.
39. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131: 830-840.
40. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST et al. Epithelial-tomesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015; 527: 472-476.
41. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al. Epithelial-tomesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527: 525-530.
42. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
43. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
44. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-1077.
45. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 2015; 6.
46. Zhang HM, Chen H, Liu W, Liu H, Gong J, Wang H et al. AnimalTFDB: a comprehensive animal transcription factor database. Nucleic Acids Res 2012; 40: D144-D149.
47. Prasetyanti PR, Zimberlin C, De Sousa EMF, Medema JP. Isolation and propagation of colon cancer stem cells. Methods Mol Biol 2013; 1035: 247-259.
48. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31.
49. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006; 22: 2825-2827.